Clinical Infectious Diseases · 1999 · 39 citations · 23 references
MedicineImmunologyPediatricsImmunizationVaccine ImmunologyVaccinologyAdverse Events Following ImmunizationPediatric ImmunizationVaccinationVaccine EfficacyVaccine SafetyVaccine-preventable DiseasesBooster Immunization In ChildrenPediatric VaccinationProtective Antibody TitersRabies VaccinesRabies VirusSevere Allergic ReactionSystemic Adverse ReactionsVaccine Safety In Infants
We evaluated the immunogenicity and safety of a chromatographically purified rabies vaccine (CPRV) compared with human diploid cell rabies vaccine (HDCV) after pre-exposure immunizations (both primary and booster). Intramuscular doses of either 0.5 mL of CPRV or 1.0 mL of HDCV were given to 400 schoolchildren on days 0, 7, 28, and 365 (booster). Adequate titers of antibody (> or = 0.15 IU/mL, as defined by the Centers for Disease Control and Prevention) were observed in serum samples from all children 14 days after primary immunization with CPRV and HDCV; the antibodies persisted in all but one child up until 1 year. Fourteen days after the primary immunization series (day 42) and 7 days after booster immunization (day 372), all children had antibody titers of > or = 0.5 IU/mL. Local and systemic reactions after primary and booster immunizations occurred significantly less frequently in the CPRV group. A severe allergic reaction (angioedema) was reported in only one child after booster immunization with HDCV. CPRV has adequate immunogenicity for primary and booster pre-exposure immunizations in children and has a better safety profile than does HDCV.
23
Allergic Reactions to Drugs and Biologic Agents
John A. Anderson · JAMA · 1987 · 235 citations
Michael E. Pichichero, Maria Deloria Knoll, Margaret B. Rennels et al. · PEDIATRICS · 1997 · 145 citations
Failure of Postexposure Treatment of Rabies in Children
Henry Wilde, Siriwan Sirikawin, A Sabcharoen et al. · Clinical Infectious Diseases · 1996 · 143 citations · Full text